Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D1ME100
- Development stage
- Phase 1
- Lead developer
- Naval Medical Research Center
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
D1ME100 is a monovalent DNA plasmid vaccine developed for dengue prevention, specifically targeting dengue serotype 1 (DENV-1). It contains the genetic material (prM and approximately 92% of the envelope (E) genes) from DENV-1, which directs host cells to produce viral proteins. When administered, the vaccine is designed to induce both humoral (antibody-mediated) and cellular immunity against the dengue virus.
02
Targets
DENV-1 antigens (Dengue virus serotype 1 antigens)
Beyond the preview
Go deeper on D1ME100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D1ME100.